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ABSTRACT
Introduction: Cancer and myocardial infarction are lethal diseases. Their prevalence is increasing 
worldwide. In both diseases, the level of oxidative stress rises because of tissue damage. The 
aim of this study was to evaluate the serum levels of heat shock protein 27 and heat shock 
protein 60 in patients with cancer and myocardial infarction, and then compare them with healthy 
individuals. Materials and Methods: After blood samples were collected from the participants, 
plasma and serum were separated from these samples for further examination. The serum levels 
of heat shock protein 27 and heat shock protein 60 were measured with related kits in 30 patients 
with cancer and 30 patients with acute myocardial infarction, followed by 30 healthy individuals. 
The collected data were then analyzed in the Statistical Package for the Social Sciences software 
(version 22). Results: The mean serum levels of heat shock protein 27 in cancer patients (25.21 
± 5.57 ng/mL) and in patients with myocardial infarction (45.23 ± 7.43) were significantly higher 
than those in healthy individuals (10.61 ± 3.11; P<0.05). In addition, the mean serum levels of 
heat shock protein 60 in patients with cancer (19.23 ± 3.41 ng/mL) and patients with myocardial 
infarction (22.23 ± 2.25 ng/mL) were significantly higher than those in healthy individuals (8.38 
± 2.53; P<0.05). Conclusion: An increase in the serum levels of heat shock proteins 27 and 60 
was observed in patients with cancer and myocardial infarction. Therefore, we can suggest that 
these biomarkers should help surgeons or physicians to diagnose the diseases.
INTRODUCTION
Despite several efforts, the prevalence of noncommunicable 
diseases is rising. Among them, heart diseases and cancers 
are the leading causes of mortality all over the world (1). 
Cancer is one of the oldest diseases of humankind, and 
despite several attempts for its therapy, its incidence is on 
the rise (2). The prevalence of cancer is high in developing 
countries such as Iran; of all cancers, gastrointestinal cancer 
is of particular importance (3). In addition, cardiovascular 
diseases are the leading cause of death and disability. They 
cause about 50% of all deaths; about 7 million people die 
annually because of cardiovascular diseases (4).
Shock proteins are produced by cells in response to ex-
posure to stressful conditions such as thermal shock, as well 
as physical, chemical, and biological stresses (5). Heat shock 
proteins (HSPs) are regulatory proteins that are divided into 
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subfamilies based on their weight. So far, 4 large protein fam-
ilies have been detected, including HSP90, HSP70, HSP60, 
and HSP27. The role of these proteins is to prevent protein 
aggregation and removal of badly twisted proteins (6). When 
HSPs bind to the P53 gene, the mutations of this gene in-
crease. This action causes a delay in the death and invasion 
of cancer cells (7, 8). Moreover, the expression of these pro-
teins in ischemic diseases induces the expression of adhesion 
molecules, causing the migration of inflammatory cells to 
the site of lesion, thereby exacerbating inflammation (7).
HSP60 and HSP27 are continuously secreted by can-
cer cells, which in turn paves the way for tumor progres-
sion (8, 9). A higher than normal level of HSP27 expression 
was detected in various cancers, for example, in breast, 
prostate, bladder, gastric, ovarian, and oral squamous car-
cinoma cancers, as well as in Hodgkin disease (5). In isch-
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emic diseases, HSP60 is overexpressed by the damaged 
cells (7, 10). Because acute myocardial infarction (AMI) 
and gastrointestinal cancers are metabolic diseases, we ex-
pect a higher expression of these proteins in both diseases. 
The aim of this study was to compare the serum levels of 
these proteins, specifically in patients and healthy people 
in our population.
MATERIALS AND METHODS
A total of 30 patients with gastrointestinal cancer confirmed 
by a pathologist and 30 individuals with AMI were recruit-
ed for this study. In addition, 30 healthy individuals were 
selected when matched with demographic factors of other 
participants. A written consent was obtained from all par-
ticipants, and the questionnaire was completed for all pa-
tients. This study was approved by the Research Council and 
Ethics Committee of Birjand University of Medical Scienc-
es Birjand, South Khorasan Province, Iran. Blood samples 
were taken from all individuals, and serum was separated 
from them; serum was stored at 80°C until used. Biomark-
ers (HSP27 and HSP60) were measured using ELISA kits 
(HSP27: Boster Biological Technology Co., Ltd; HSP60: 
Hangzhou Eastbiopharm Co., Ltd). Statistical analyses were 
performed using the Statistical Package for the Social Sci-
ences software, version 22 (SPSS, Chicago, IL, USA). P<.05 
was considered statistically significant.
RESULTS
The patients with AMI and gastrointestinal cancer were 
compared with 30 healthy subjects in terms of the HSP27 
and HSP60 levels. Immunological findings showed that 
there was a significant increase in the HSP27 levels in the 
serum of patients with AMI and gastrointestinal cancers and 
healthy subjects (P<0.05; Table 1).
DISCUSSION
Gastrointestinal cancer and AMI are two of the most im-
portant diseases of the 21st century with inflammato-
ry and oxidative stress conditions. Both diseases cause 
huge fatality in both developed countries and developing 
countries (1, 11). During inflammation, certain types of 
cytokines such as tissue necrosis factor-alpha (TNF-α) 
and interleukin 1 (IL-1) are secreted, which can induce the 
production of HSPs (12). The aim of this study was to de-
termine the serum levels of HSP27 and HSP60 in patients 
with cancer and patients with AMI and to compare the lev-
els with those in healthy people.
This study showed that the levels of HSP27 and HSP60 
were significantly higher in patient groups compared with 
healthy subjects. The rate of HSP27 in patients with cancer 
and AMI increased 2.5 and 4.5 times, respectively, and the 
rate of HSP60 in patients with cancer and AMI increased 2.3 
and 2.7 times, respectively. Consistent with our study, Zhang 
et al showed increased levels of HSP60 in the case of stroke, 
which may be caused by myocardial necrosis and vascular 
endothelial dysfunction. In line with Zhang et al, several 
studies have shown that the level of HSP60 increases the 
production of proinflammatory factors, such as TNF-α, IL-1, 
IL-6, and IL-12, and sticky molecules such as selectins and 
integrins; therefore, HSP60 plays a major role in the devel-
opment of atherosclerosis and predisposes cells to AMI (13). 
Also, de Haan et al showed that HSP27 and HSP70 serum 
levels significantly increased inflammation caused by car-
diomyopathy ischemia (14). A study by Abharzanjani et al 
showed that the levels of HSP27 are significantly increased 
after AMI caused by oxidative stress (11).
HSP60 is actively secreted from tumor cells as well (15). 
This inflammatory biomarker has a significant relationship 
with the invasive form of cancers, and it is significantly in-
volved in tissue cancer and lymph node (15). The results of 
Xiao-Shan et al study showed that the prognosis of gastro-
intestinal cancer patients with a high level of HSP60 protein 
is poor (16). In addition, the results of the studies conducted 
by Faried et al and Cappello et al showed that this biomarker 
plays a major role in the development of cancers such as 
the esophageal and intestinal cancers (17, 18). Furthermore, 
various articles have reported a higher amount of HSP60 
protein in inflammatory bowel disease such as the Crohn 
disease (15).
Ce´line Hamelin’s results showed that the expression 
level of HSP27 protein increased significantly during liver 
cancer. However, this increase was not significantly correlat-
ed with tumor variations (19). The excessive presence of 
this protein (HSP27) can cause epithelial and mesenchymal 
changes. Besides, HSP27 expression can cause drug resis-
tance in cancers such as pancreatic cancer (20).
CONCLUSION
The results of the present study showed that the levels of 
HSP27 and HSP60 were significantly increased in patients 
with gastrointestinal cancers and AMI compared with those 
in healthy individuals. It seems that these two HSPs can be 
used as a prognostic factor for diagnosing AMI and gastro-
intestinal cancer.
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Table 1. Levels of HSP27 and HSP60 in serum of 
patients with AMI and gastrointestinal cancers and 
normal groups
HSP60
(ng/mL)
HSP27
(ng/mL)
Biochemical 
Markers
Population Studied
8/38±2/5310/61±3/11Normal people
19/23±3/41a25/21±5/57aCancer patients
22/23±2/25a45/23±7/43aAMI patients
(Abbreviations: a. HSP: heat shock protein, b. AMI: acute myocardial 
infarction)
aP<0.05 (case group compared with the normal group).
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